Home / Peptides / Tirzepatide: Trial Evidence, Risks and Compounded Versions
Tirzepatide: Trial Evidence, Risks and Compounded Versions
What tirzepatide (Zepbound, Mounjaro) did in major trials, what happens to lean mass, its boxed warning, and where compounded versions stand with FDA.
On this page
Quick facts
Fact sheet
- U.S. status
- Strongest evidence
- Human trials
- Status verified
An FDA-approved drug with large trials for weight, sleep apnea and type 2 diabetes, and a body-composition question that headlines tend to skip. Here is what the trials found, what they did not test, and why a compounded version is a different product.
Key takeaways
- Tirzepatide is FDA-approved. It is sold as Zepbound (weight and sleep apnea) and Mounjaro (type 2 diabetes), each for the uses on its own label.
- The evidence is strong for weight, sleep apnea with obesity and blood sugar control. It comes from randomized trials; the two head-to-head trials were funded by the manufacturer.
- Some of the weight lost is lean mass. In a body-composition substudy, about a quarter of the weight lost was lean mass. Lean mass is not the same as muscle or strength, and that analysis did not measure strength.
- On heart events, it was non-inferior to dulaglutide, not superior.
- It carries a boxed warning for thyroid C-cell tumors, seen in rodents. Relevance to humans has not been determined.
- Compounded tirzepatide is not FDA-approved. FDA does not review compounded drugs for safety, effectiveness or quality before they are sold.
Is tirzepatide FDA-approved, and for what?
Yes. Brand names are used here only to identify the approved products.
| Product | What the label says it is for | Source |
|---|---|---|
| Zepbound | Reducing weight and keeping it off in adults with obesity, or with overweight plus a weight-related condition; moderate-to-severe obstructive sleep apnea in adults with obesity | Zepbound label |
| Mounjaro | Blood sugar control in type 2 diabetes in adults and in children 10 and older; reducing major cardiovascular events in adults with type 2 diabetes at high cardiovascular risk (added to the label in August 2026) | Mounjaro label |
Dosing is set by each label and your prescriber. This guide does not give doses.
What did the major trials find?
Every trial below is randomized and in people. Results are averages; individual responses vary. The two head-to-head trials were funded by Lilly, which makes tirzepatide.
| Goal | Trial | Who was studied | What happened |
|---|---|---|---|
| Weight | SURMOUNT-1 | 2,539 adults with obesity, or overweight plus a weight-related condition, no diabetes, 72 weeks | Average weight change −15.0% to −20.9% depending on dose arm vs −3.1% on placebo. Stopping because of side effects: 4.3% to 7.1% vs 2.6% |
| Weight vs semaglutide | SURMOUNT-5 | 751 adults with obesity, no diabetes, open-label, 72 weeks | −20.2% vs −13.7% with semaglutide; waist −18.4 vs −13.0 cm. Funded by Lilly |
| Blood sugar vs semaglutide | SURPASS-2 | 1,879 adults with type 2 diabetes, open-label, 40 weeks | HbA1c fell 2.01 to 2.30 points on tirzepatide vs 1.86 on semaglutide 1 mg, and weight differed by 1.9 to 5.5 kg in tirzepatide’s favor. Serious adverse events in 5% to 7% vs 3%. Funded by Lilly |
| Sleep apnea | SURMOUNT-OSA | 469 adults with moderate-to-severe apnea and obesity, 52 weeks (enrollment) | Apnea-hypopnea index fell 25.3 vs 5.3 events per hour in people not using PAP therapy, and 29.3 vs 5.5 in people using it |
| Heart events | SURPASS-CVOT | 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease, vs dulaglutide | Major cardiovascular events 12.2% vs 13.1%; HR 0.92 (95.3% CI 0.83–1.01). Non-inferior, not superior (p=0.09) |
How strong is each result?
- Weight, sleep apnea with obesity and blood sugar: strong. Large trials, large effects and approved indications.
- Heart events: the label includes a cardiovascular indication, but the trial supports non-inferiority to dulaglutide. It does not show tirzepatide beats dulaglutide, and we found no trial comparing tirzepatide with semaglutide on heart events.
- Head-to-head with semaglutide: two open-label trials, both funded by Lilly, favored tirzepatide on weight (SURMOUNT-5) and on blood sugar and weight in type 2 diabetes (SURPASS-2). SURPASS-2 used a 1 mg semaglutide comparator, not the higher dose used for obesity. See the full comparison.
How much of the weight lost is muscle?
This is the question many people have, and the trials answer only part of it.
- Lean mass fell. In a body-composition substudy of SURMOUNT-1 (160 people, 72 weeks), weight fell 21.3% on tirzepatide vs 5.3% on placebo, fat mass fell 33.9% vs 8.2%, and lean mass fell 10.9% vs 2.6%. About 75% of the weight lost was fat and about 25% lean mass, in both groups.
- The label says tirzepatide produces “greater fat mass loss than lean mass loss” (Zepbound label).
- Across GLP-1 drugs, a 2025 network meta-analysis of 22 trials (2,258 people) found lean mass fell by 0.86 kg on average, about a quarter of the weight lost, while lean mass as a percentage of baseline did not change. Tirzepatide and semaglutide were among the drugs that preserved it least well, and also among those that removed the most weight.
- The limit: lean mass is not muscle, and these analyses reported body composition, not strength or function. They do not tell you whether anyone lost physical performance, or whether resistance training or protein intake changes the result. We did not review data on that.
What are the risks?
From the Zepbound label:
- Boxed warning: risk of thyroid C-cell tumors. It is contraindicated in people with a personal or family history of medullary thyroid carcinoma or with MEN 2. The tumors were seen in rats; whether the risk applies to humans has not been determined.
- Warnings: severe gastrointestinal reactions, acute kidney injury from dehydration, gallbladder disease, pancreatitis, hypersensitivity, low blood sugar, diabetic retinopathy complications, and lung aspiration during anesthesia or deep sedation.
- Combining products: the label does not recommend using it with another GLP-1 product or another tirzepatide product.
- Suicidal behavior and ideation: this warning was removed from the label in February 2026.
Is compounded tirzepatide the same as Zepbound or Mounjaro?
No. FDA says compounded drugs are not reviewed for safety, effectiveness or quality before they are marketed, and that a compounded product should not be called “generic” or described as “the same as” an approved drug. Details, as of Oct. 31, 2026:
- Tirzepatide is not on the FDA drug shortage list or the 503B bulk substances list (FDA, April 1, 2026). In May 2026 FDA proposed not adding it to the 503B list. We found no final rule.
- Pharmacies’ broader latitude during the shortage ended March 5, 2025. Compounders remain limited in making products that are “essentially copies” of approved drugs.
- A Sept. 18, 2026 FDA warning letter to a compounding pharmacy said a tirzepatide-plus-niacinamide product and others appear to be essentially copies of approved drugs. A warning letter is an agency position, not a court ruling.
- FDA is aware of fraudulent products and adverse events, including doses above label amounts.
HHS’s Oct. 30, 2026 interim compounding policy covers six other peptides and does not include tirzepatide. We do not recommend pharmacies or telehealth services.
What should you ask your doctor?
- Do I have a personal or family history of medullary thyroid carcinoma or MEN 2? (It rules tirzepatide out.)
- Have I had pancreatitis or gallbladder disease, or do I have diabetic retinopathy?
- Do I take insulin or another diabetes medicine, and could my dose need to change?
- How will we watch my body composition and strength while I lose weight?
- Which product am I being prescribed: an FDA-approved one, or a compounded one? Who makes it?
Frequently asked questions
Is tirzepatide the same as Zepbound?
Tirzepatide is the active ingredient in Zepbound and Mounjaro. They are approved for different uses. Check each label.
Is tirzepatide stronger than semaglutide?
Two Lilly-funded, open-label trials favored tirzepatide on weight (in adults with obesity) and on blood sugar and weight (in type 2 diabetes). “Stronger” is not established for other outcomes.
Does tirzepatide make you lose muscle?
About a quarter of the weight lost in one substudy was lean mass, which includes muscle but is not the same thing. The analysis did not measure strength.
Is tirzepatide better for the heart than other diabetes drugs?
Not shown. SURPASS-CVOT found it non-inferior to dulaglutide, not superior.
Can compounded tirzepatide replace the brand-name drug?
FDA says a compounded product is not the same as an approved one and has not been reviewed for safety, effectiveness or quality. Talk to a prescriber about your options.
Sources we checked
- Zepbound prescribing information (DailyMed, rev. 08/2026)FDA. Accessed .
- Mounjaro prescribing information (DailyMed)FDA. Accessed .
- SURMOUNT-1 trial (PubMed)PubMed. Accessed .
- SURMOUNT-5 trial: tirzepatide vs semaglutide (PubMed)PubMed. Accessed .
- SURPASS-2 trial: tirzepatide vs semaglutide in type 2 diabetes (PubMed)PubMed. Accessed .
- SURMOUNT-OSA trial (PubMed)PubMed. Accessed .
- SURMOUNT-OSA trial, participant numbers (PubMed)PubMed. Accessed .
- SURPASS-CVOT trial (PubMed)PubMed. Accessed .
- SURMOUNT-1 body composition substudy (PubMed)PubMed. Accessed .
- Network meta-analysis of GLP-1 drugs and lean mass, 2025 (PubMed)PubMed. Accessed .
- HHS: Enforcement Discretion Policy, with Appendices A and BOther. Accessed .
- FDA clarifies policies for compounders as national GLP-1 supply stabilizesFDA. Accessed .
- Federal Register: proposed 503B bulk drug substances list (May 1, 2026)Other. Accessed .
- FDA warning letter to a compounding pharmacy, Sept. 18, 2026FDA. Accessed .
- FDA's concerns with unapproved GLP-1 drugs used for weight lossFDA. Accessed .
- FDA: telehealth companies and promoting compounded drugsFDA. Accessed .
Written and maintained by the Best Peptides For Editorial Team. How we rate evidence.